A recent trial found an excess of muscle-related adverse events associated with statins only when patients were aware that statin therapy was being used. The trial included a randomized double-blind placebo-controlled phase, in which 10,180 patients received atorvastatin or a placebo, and a subsequent non-randomized non-blind extension phase, in which all patients were offered atorvastatin open label. During the blinded phase, muscle-related adverse events were reported at a similar rate between groups, but in the non-blinded phase, statin users reported a 41% higher rate of muscle pain or weakness than those taking placebo. The findings are published in The Lancet.